On July 21, 2026, Bluejay Diagnostics announced the completion of patient enrollment for its SYMON-II multicenter clinical validation study ahead of schedule. The study enrolled 750 patients to evaluate the Symphony IL-6 test's ability to assess 28-day all-cause mortality risk in sepsis patients admitted to the ICU. Preliminary observations show an approximately 17% 28-day mortality rate. The company intends to use the resulting clinical dataset to support future FDA 510(k) regulatory submissions and commercialization of the Symphony platform. The company operates in the medical diagnostics industry, developing rapid, near-patient diagnostic technologies for critical care.
